Food Robotics Market Trends 2019

Recently, Starship Technologies has rolled out its robot delivery service to one of the U.S largest universities, UW-Madison. The university has deployed 30 robots for food delivery in the campus. 

Robotics has changed the way the food industry used to work. It is transforming most of the sectors of the food industry from manufacturing, packaging to delivery and tracking. 

This is not the first university to deploy robot delivery service. Many universities have already experimented and results were fruitful. 

These robots are the small box type tiny vehicles that can carry weight up to 20 pounds. The delivery is fast-moving depending on the item and distance. 

The Gen Z population is advancing and they want services from a few taps on their smartphone. Colleges are finding ways to offer students convenient ways to order food to save time. 

The recent global food robotics market research report suggests that the market is expected to grow at a substantial rate by 2023.

Robotics in the food industry has improved the efficiency of the working process. Many food processing and packaging companies are adopting robotics as well as artificial intelligence to improve food safety, reduce workers’ injuries and systematize the process. 

Robotics is empowering food manufacturers to keep records of the consumers. It is assisting manufacturing companies to track the products and demand of the market. This has helped manufacturers to keep abreast of growing trends of the market and accordingly match the production. Robotics handle food safely to prevent any contamination.

Due to the growing concern for food safety and hygiene, many new companies are emerging to come up with cutting-edge robotic technologies. 

KUKA Robotics, the leading manufacturing company of Europe that provides robots for the entire food industry process chain.  They have a wide range of robots that serve various needs of the food industry. The robots are designed for hygienic maintenance,  food packaging, custom processing, and logistics systems and for the food processing industry. 

The adoption of robotic systems has observed the growth of several food sectors such as meat processing, dairy and dairy products, and ready foods.

Also, other technologies are revamping with food robotics. For example, machine vision technology is highly used in food robotics due to its use for food quality assurance.

Recently, Singapore’s Food Tech company have launched the country’s first robotic concept restaurant. The restaurant is fully-automated, includes taking orders as well as cooking. The food is prepared by the robot chef, D.I.A.N.A, manufactured by Epic Food and Beverages.

Is there any risk factor involved?

The concerns raised when high-tech Henn na Hotel in Japan where robots are in service, reported that its robots in the room can be hacked. The questions raised for the security of other machines as well. 

However, there is no reason to worry about hacking. Food data usually collect data on Who bought what, what time of day it was, where were they, what was the weather outside, how much did they spend.

But attention should be paid to how the data is used in the food industry. The consumers are not aware of what they are signing up for. 

Food demand is increasing with the increasing population. The food suppliers are under pressure to serve the demands.  The companies are adopting robotics for countless reasons. The food robotics market is projected to see lucrative growth.

Why are people saying that the future of bioprinting is here?

BioprintingIn a world where humans are incapable of building a cell from the scratch, it is possible to simply “print” an entire human organ within a time frame of about 12 hours. Seems infeasible? That is why people are saying that the future of bioprinting is here!

From woodblock printing to the press, the field of lithography has seen great advancements. Currently, 3D printing technologies are in the buzz have garnered a good amount of traction for their contribution to various industries of the global market. Healthcare is only the next. The bioprinting industry market has enabled us humans to use biocompatible materials, cells, and their supporting components and build an entire and fully-functional human organ. Bioprinted organs have various applications in the current day

  • They used in the field of regenerative medicine to form organs suitable to transplantation. Healthcare market research reports say that this has greatly reduced the chances of the patient’s body refusing the organ.
  • They can be used for a high-throughput processing and production of tissue models for research
  • Complex models and protein interactions can be constructed using this technology. So, instead of animal models, drug discovery and toxicology studies can happen on 3D bioprinted material for more reliable results.

The global bioprinting industry market is seen to be highly promising with more possibilities to be unveiled in the near future. But it is interesting to note that this advanced a technology is based on the simple concept of layer-by-layer printing to form a 3D structure!

Market research reports say that the origins of 3D technology and known to be in the 80s. Bioprinting, like any other 3D printing process, is additive in nature. Successive layers of a material are amalgamated to form an entire three-dimensional structure. Complex geometries of the biological components are no hurdle in the production process but may make the process more time-consuming.

Biologically inspired engineering has been put to use to solve a number of technological problems and not just healthcare. So, insights from building an organ may be helpful to various other sectors, surprisingly including the manufacturing of airplanes! And, on the other hand, the technology of 3D printing is itself inspired by biological processes like the development of an embryo.

Bioprinting is already an alternative to many traditional approaches and biotechnology market research reports say that the paradigm is soon expected to shift to in-vivo bioprinting as a developmental goal. The difficult challenges need to be addressed increasingly to realize the full potential of 3D bioprinting.

What’s in store for Biosimilar Market- Global forecast 2021

The international market for biosimilar is predicted to grow from USD 3.39 billion in 2016 to USD 10.90 billion by the year 2021 at the compound annual rate (CAGR) of 26.3%.

The market on the basis of products, is segmented into non-glycosylated proteins, recombinant peptides and recombinant glycosylated proteins. According to the market research, the recombinant non-glycosylated segment estimated to hold the largest share of the biosimilars market, in 2016.

The growth in the market is citied to the new product launches, growing incidence of diabetes, cost-efficiency, introduction of many other biosimilar versions of insulin in development.

Key factors driving and impeding the growth of the market

Several high profile biologics patent expiry dates are arriving in the next 5-10 years

The expiration dates of the patents and other intellectual property rights of biological innovators over the next ten years, have given new opportunities for biosimilars to penetrate the market and therefore increase competition in the industry of biosimilars market.

Key therapy areas such as the diabetes (insulin), oncology (mAbs) and rheumatoid arthritis (mAbs) will lead growth during 2016 through 2020.

Patients and physicians to be at center stage as prescription and usage rates are linked to Return on Investments models

The key reasons why physicians hesitate to endorse biosimilar, as per a healthcare market research is due to – accurate information before prescription, effectivity, safety issues, substitution of drugs and visibility of total costs.

These dynamics make it challenging to predict the growth trajectory of the biosimilars market, which is expected to boom after 2020.

High cost circumstances influences the government to promote biosimilars

The use of innovator biologics comes with a high price (especially, monoclonal antibodies) which have resulted in many governments giving incentives for biosimilar use.

As per market research few countries in the Europe like – Denmark, Germany and Netherlands have introduced an assortment of incentive programs and developed strategic plans for rebates and discounted prices.

For e.g., Remicade, is mainly used for Rheumatoid Arthritis, Crohn’s disease, ulcerative colitis and plaque psoriasis. The European patent for it expired in 2015, giving way for biosimilars to be commercialized with discounted price up to 70% compared to Remicade cost.

Clash of key industry players in Europe and emerging markets

The rising number of biosimilar approvals in Latin America, India and Japan along with financial capability of big pharma and generic companies are reasons for the emergence of new participants in the market.

Drug delivery device becoming the new normal

Other than price, biosimilar market has differentiated itself with monitor dosing, higher safety, advanced compliance, easy usage and volume control.

Why Cord Blood Storage is Important in Stem Cell Banking?

Cord Blood Storage Cord blood is the blood found in baby’s umbilical cord, which has stems cells that can also grow in organs, tissues and blood vessels. This can be later utilized for a person to treat several diseases such as immune deficiency, bleeding disorder, cancer, and a lot more, which sometimes even modern day standard medications can’t treat. Today, cord blood banking is one of the booming segments in healthcare. Cord blood is one of the dominant transplant sources for United States’ patients of mixed racial or minority heritage.

More of developing countries are adopting the healthcare service. In the U.S. the cord blood storage started in 1995, and China is also advancing to grasp a firmer market share. Market dynamics for the industry is different in different regions. In France and Italy there is no private institution that can control cord blood storage banking, while in Ecuador there are restrictions on asking women about her options to cord blood stem cell in the initial 6 months of her pregnancy.

What are the Advantages?

The baby’s cord blood can be either stored in family cord blood bank for the use of immediate family or donated to public cord blood bank. The first stem cell transplant happened in 1957, after which more of such procedures took place. Why cord blood cells are preferred is because these are purer, more adaptable and younger than other stem cells. These were never exposed to chemicals, pollutants of environment or chemicals, thus there is no risk of altered cell function.

In case a person does not have his/her cord blood saved, then a transplant from the other is an option. It may cost more than previous method, but is life saving nonetheless.  In 2012, 44 percent of African American patients and 38 percent of Hispanic patients underwent stem cell transplants from cord blood. Increasing number of adults is getting cord blood transplants. Sometimes the transplants are derived from two cord blood donations in case a single one does not contain sufficient stem cells. A greater than 33,900 cord blood units were shipped globally for transplants a few years ago.

Why Cord Blood Cells are in High Demand?

Apart from cord blood stem cells, bone marrow stem cells are also used in transplant. However, the former has lesser immune reactions and increased flexibility in HLA-mismatched cord blood units than the counterparts. The first transplant of the kinds was done in 1988 and since then the blood from umbilical cord has helped more than 30,000 people worldwide. However, the industry too faces some challenges moreover because parents do not actually know the advantages of cord blood storage.

Some of the threats are the expensive cord blood transplantation processes, one can cost about USD 200-300, difficult training obstetricians on cellular therapies, lack of public coverage over the healthcare, and regulations for accreditation requirements. People may be hesitant to preserve their child’s umbilical cord blood cells thinking will it even come to use in future or not. They may not be educated by doctor earlier as to why agreeing to cord blood storage can work well during medical emergencies.

Medical Expertise

Dr. Sonali S. Shetye is one of the leading infertility specialists, and has a strong background in medical industry. Her expertise also lies in laparoscopy , Gynaecology and obstetrics. If you have any queries pertaining to specified fields, please feel free to contact us at for professional guidance.

MIT Chemists Introduce Effective Molecular Treatment for Deadly Cancers


Every year, the world records 12 million cases of diagnosed cancer, and some its types can be treated with available treatments. But, there are some forms, which do not respond to present approaches. This is where drug delivery systems for cancer faces short-comes. Innovative and novel methods to treatments are being explored. These are based on micro-particle, which carry anti-cancer agents.

Such particles are injected in the affected person’s bloodstream, and directed to tumor through magnetic field of targeted drug reach. Professor Paula T. Hammond, the head of MIT’s Department of Chemical Engineering, opened up about the remedy in a conference. The team she leads us engineering a nano-particle that is one-hundredth measure of a human hair, and may be able to treat serious cancers that do not respond well to drugs.

However, the costs to trial of novel remedies today may seem a lot, In future it will yield good results. As per market research reports, clinical trials for global advanced drug delivery industry will stand at $227.3 billion by the year 2020. Here is how the super-powerful molecular treatment devised will fight deadly cancers.

New Molecular Treatment for Cancer

MIT chemists wish to create a cancer-restraining agent that will be introduced in patient’s bloodsteam, which goes to penetrate tumor tissues. The nano-particle will be small enough so as to get into the cancer cell. The nano-particle core is a tiny capsule which consists of chemotherapy drug. Thus poison will end life of tumor cells, and around the core, the experts will wrap thin nanometers of siRNA (small interfering RNA), a gene blocker.

The same is a strong negatively charged element that is covered by a protective later of polymer (positively charged). The oppositely charged molecules will stick together due to charge attraction that will give a protective later to prevent the siRNA deterioration in blood. The siRNA is a collection of molecules, which is utilized to stop a specific gene in a cell. The scientists are keen about the enormous clinical potention of such gene blockers for drug delivery and diagnostics.

A body has cells, which in bloodstream can attack anything that is foreign. The team and Hammond are devising a technique for deploying nano-particle without causing any problem to the patient. The way out was adding another negatively charged cover about the nano-particle that services the purpose of creating clod of water molecules for nano-particles for cloaking effect. It will also consist of molecules to bind at tumor cell. When in the cancer cell, it is easy to deploy the nano-particle.

Killing the Dangerous Tumor

When siRNA is employed, cancer cell is defenseless. A chemotherapy drug exudes from capsule to destroy tumor cells efficiently. On using sufficient measure of gene blockers, it is possible to answer many different types of mutations that will clear out other tumors without leaving remnants. The MIT researchers say that nano-particles were tested on animals with triple-negative breast cancer, and the therapy did reduce size of tumors, and some of the cancer cells were eliminated.

Hammond thinks her approach may be personalized. There are more treatments being tested and developed. According to the healthcare market research reports, the UT Southwestern Medical Center experts revealed findings of Stereotactic Body Radiation Therapy, which proved to be more effective than other traditional treatment, with cure rate of 98.6 percent.

As for siRNA therapy, it is backed by evidence that cardiovascular drug delivery is most innovative means in therapeutics underlying RNA interference. Rest is supposed to be seen how the treatment progressed. More clinical trials will be needed, until the drug delivery can be made available to health authority and organizations to give it a clean chit, and then present it to the market.